NCT06234150 (ADANC) is a NA clinical trial of Aerobic dance in Breast Neoplasms, sponsored by The First Affiliated Hospital with Nanjing Medical University.

Who is sponsoring NCT06234150?

NCT06234150 is sponsored by The First Affiliated Hospital with Nanjing Medical University.

What drugs are being tested in NCT06234150?

Interventions in NCT06234150: Aerobic dance, Fast-walking.

What condition does NCT06234150 study?

NCT06234150 studies Breast Neoplasms, Exercise Therapy, Chemotherapy-Related Cognitive Impairment, Cognitive Dysfunction, Dance Therapy.

Is NCT06234150 still recruiting?

NCT06234150 is currently not yet recruiting. Last updated 20 February 2024.

Last reviewed 2024-02-20 · How we verify

NCT06234150: ADANC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aerobic Dance During Chemotherapy in Breast Cancer Patients With Cognitive Impairment

Not yet recruiting NA Last updated 20 February 2024

What this trial tests

NA trial testing Aerobic dance in Breast Neoplasms in 90 participants. Not yet recruiting.

Timeline

1 April 2024

Primary endpoint
1 July 2026

1 January 2027

Quick facts

Lead sponsor	The First Affiliated Hospital with Nanjing Medical University
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	90
Start date	1 April 2024
Primary completion	1 July 2026
Estimated completion	1 January 2027
Sites	1 location across China

Drugs / interventions tested

Aerobic dance
Fast-walking

Conditions studied

Breast Neoplasms — all drugs for Breast Neoplasms →
Exercise Therapy — all drugs for Exercise Therapy →
Chemotherapy-Related Cognitive Impairment — all drugs for Chemotherapy-Related Cognitive Impairment →
Cognitive Dysfunction — all drugs for Cognitive Dysfunction →

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Who can join

Adults 18 to 65, female only, with Breast Neoplasms or Exercise Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn about breast cancer patients. The main questions it aims to answer are: * Does Aerobic Dance During Chemotherapy Improve Cognitive Function in Breast Cancer Patients？ * Does the efficacy of aerobic dance differ from fast walking of equal intensity？ Recruited patients will be randomly assigned to three groups: (1) aerobic dance group, (2) fast walking group, and (3) usual care group. The aerobic dance and fast-walking groups participated in supervised exercise lasting 50 minutes thrice a week for 12 weeks. The goal of this study's findings is to develop practical strategies for managing breast cancer-related cognitive impairment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Aerobic dance during chemotherapy in patients with breast cancer with cognitive impairment (ADANC): protocol for an assessor-blinded randomised clinical trial.
Cheng Y, Xu L, Xia N, Wang J, et al · · 2025 · cited 1× · PMID 41106863 · DOI 10.1136/bmjopen-2024-092003

Verify or expand the search:

Other recruiting trials for Breast Neoplasms

Currently open trials in the same condition.

NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
NCT07500428 — Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models · recruiting
NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
NCT07222215 — PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) · Phase 2 · recruiting
NCT07465393 — Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors · NA · recruiting

Other The First Affiliated Hospital with Nanjing Medical University trials

Trials by the same sponsor.

NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
NCT07523789 — Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC · not yet recruiting
NCT07464756 — SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer · Phase 2 · not yet recruiting
NCT07482826 — Full-Endoscopic Decompression vs. Endoscopic Lumbar Fusion for Middle-Aged and Older Adults With Spinal Stenosis · NA · not yet recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06234150 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital with Nanjing Medical University
Last refreshed: 20 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06234150.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing